News & Press Releases

Access the latest news about Lipidor, our current projects, publications and collaborations. Thank you for your interest in Lipidor!

Subscribe

January 24, 2024

Lipidor completes SEK 1.7 million sale of animal segment patent

STOCKHOLM, Sweden, 24th January 2024 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) today announces that one of the company's patents, previously out-licensed to Emollivet AB, has now been sold to the same party. The sale is aimed at strengthening Lipidor's short term cash position. Since its inception…

June 8, 2021

Bulletin from the annual general meeting of Lipidor AB (publ)

STOCKHOLM, Sweden, 8 June 2021: The following resolutions were passed at the annual general meeting (the “AGM”) of Lipidor (publ) (the “Company”)…

May 24, 2021

NOTICE OF EXTRAORDINARY GENERAL MEETING IN LIPIDOR AB (publ)

STOCKHOLM, Sweden, 24 May 2021: The shareholders of Lipidor AB (publ) reg. no. 556779-7500 (the “Company” or “Lipidor”) are hereby given notice…

May 7, 2021

NOTICE OF ANNUAL GENERAL MEETING IN LIPIDOR AB (publ)

STOCKHOLM, Sweden, 7th May 2021: The shareholders of Lipidor AB (publ) reg. no. 556779-7500 (“Lipidor” or the “Company”) are hereby given notice…

May 6, 2021

Lipidor publishes interim report for Q1 2021

STOCKHOLM, Sweden, 6 May 2021: Today, Lipidor AB (publ) (Nasdaq First North: LIPI) publishes its interim report for the period January –…

April 23, 2021

Lipidor publishes annual report for 2020

Stockholm, Sweden, 23 April 2021 – Lipidor AB (publ) (Nasdaq First North: LIPI) today announces that the company will publish its annual…

April 23, 2021

Lipidor’s subsidiary Emollivet takes the next step towards launch and receives funding from Vinnova

Stockholm, Sweden, 23 April 2021 – Sweden's innovation authority Vinnova is investing in Lipidor's subsidiary Emollivet. The funding from Vinnova is for…

April 22, 2021

Lipidor – update on the company’s phase III clinical trial of drug candidate AKP02 for treatment of psoriasis

Stockholm, Sweden, 22 April 2021 – Lipidor AB (publ) (Nasdaq First North: LIPI) today provides an update on the planned Phase III…

February 23, 2021

Lipidor AB (publ) publishes year-end report for 2020

Stockholm, 23 February 2021: Today, Lipidor AB publishes its year-end report for the period 1 January – 31 December 2020. The report…

January 18, 2021

Lipidor and Cannassure enter exclusive licensing agreement regarding topical medical cannabis products based on Lipidor’s AKVANO[®] technology

STOCKHOLM, Sweden, 18 January 2021 – Lipidor AB (Nasdaq First North:LIPI) today announced that the Company has signed an exclusive licensing agreement…

December 16, 2020

Lipidor signs cooperation agreement with contract manufacturer to offer licensees the opportunity for GMP production

STOCKHOLM, Sweden, 16 December 2020 – Lipidor AB (Nasdaq First North:LIPI) announced today that the Company has signed a new cooperation agreement…